Discussing radiotherapy, AAA and CEO leadership with Riccardo Canevari: CEO of Radiopharm Theranostics

Discussing radiotherapy, AAA and CEO leadership with Riccardo Canevari: CEO of Radiopharm Theranostics

In this episode, Charles talks with Riccardo Canevari, the managing director and CEO of Radiopharm Theranostics, a company that is innovating the way we see cancer. They talked about his leadership journey in transitioning from leading 110k employees to a 3-man startup team. He also discusses launching innovative cancer treatments such as Luziterra and BluVicto and the challenges of selling them. He also highlights the importance of mission-driven work in biotech and the promise of radiopharmaceuticals in cancer treatment.

Here's what you are in for:

00:00 Ricardo's Journey From Milan to Pharma Leader

00:19 Family's Influence in Early Life

03:25 Ricardo's Career Path from Chemistry to Pharma

05:38 Highs and Lows in Pharma Industry

05:51 Leadership Lessons

10:27 Taking the new role as the head of Radio Pharm

17:59 Building a 3-man start up team

30:24 Reflecting on Leadership and Advancement

35:41 The Future of Radiotherapy

About Riccardo Canevari

Riccardo is an experienced leader in specialty pharma, cancer care, and radiopharmaceuticals. He served as the Chief Commercial Officer at Advanced Accelerator Applications, a leading company owned by Novartis. There, he led commercial strategies in around 20 countries. His main focus was on expanding the market for Lutathera and preparing for the launch of Lu-PSMA 617 to treat advanced prostate cancer. Before this, Riccardo held top positions at Novartis Oncology. He oversaw the successful introduction of breast cancer drugs like KISQALI and PIQRAY. He also gained extensive experience from different roles at Novartis Pharma and Ethicon/Johnson & Johnson.

Connect with Riccardo:

LinkedIn: https://www.linkedin.com/in/riccardo-canevari-7239931/

Website: https://www.radiopharmtheranostics.com/


About Charles

Charles Spence leads Discera, a leading recruitment firm specializing in the biopharma industry.


He graduated with a biomedical degree, has worked in hospitals (including translation work in Seoul, South Korea), and also spent years doing diabetes research. After doing research and travel, a career in business and science felt the most appropriate.


In 2023, Charles decided to launch his firm - Discera Search. A firm committed to solving the

biggest talent needs of Early clinical stage SME biotechs on the East Coast and DACH.


Connect with Charles:

LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/

Website: https://www.discera-search.com/

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(74)

Eliot Forster, CEO at Levicept on 30 Years in Pharma, Running a Six-Person Biotech, and the Future of European Drug Development

Eliot Forster, CEO at Levicept on 30 Years in Pharma, Running a Six-Person Biotech, and the Future of European Drug Development

In this episode, I talked with Eliot Forster, CEO of Levicept, a neurophysiologist-turned biotech veteran with 30+ years of experience across Big Pharma and a series of CEO roles. We get into clinical...

7 Syys 45min

Michael Zaiac, Medical Affairs Lead for Oncology at Daiichi Sankyo on 30 Years of Hiring Lessons, The ADC Wave, and Building Teams in a Fast-Moving Pipeline

Michael Zaiac, Medical Affairs Lead for Oncology at Daiichi Sankyo on 30 Years of Hiring Lessons, The ADC Wave, and Building Teams in a Fast-Moving Pipeline

In this episode, I talked with Michael Zaiac, Medical Affairs Lead for Oncology across Europe and Canada at Daiichi Sankyo — a trained surgical oncologist who walked away from the operating table, mov...

24 Elo 39min

Juho Jalkanen, CEO at Faron Pharmaceuticals on From Surgeon to CEO, Rethinking Boards, and Fighting for the Right Science

Juho Jalkanen, CEO at Faron Pharmaceuticals on From Surgeon to CEO, Rethinking Boards, and Fighting for the Right Science

In this episode, I talked with Dr. Juho Jalkanen, CEO of Faron Pharmaceuticals — a publicly listed Finnish biotech building novel immunotherapies for blood cancers. Juho's path is unlike most you'll h...

10 Elo 37min

Tobias Kampfenkel, MD, MHBA, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine, on Transformative Drugs in Oncology and Autoimmunity: It's Always the Team!

Tobias Kampfenkel, MD, MHBA, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine, on Transformative Drugs in Oncology and Autoimmunity: It's Always the Team!

In this episode, I talked with Dr. Tobias Kampfenkel, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine. Tobias spent nearly a decade at Janssen building ...

15 Kesä 39min

Sofia Heigis, CEO of OncoPeptides, From Sales Rep to CEO, Being "Present", and Hiring for Self-Insight

Sofia Heigis, CEO of OncoPeptides, From Sales Rep to CEO, Being "Present", and Hiring for Self-Insight

In this episode, I talked with Sofia Heigis, Chief Executive Officer of OncoPeptides, about a career path that did not start where she expected. Sofia originally wanted to move into clinical operation...

31 Touko 38min

Jens Lindberg, CEO at Medivir, on The Biotech Rollercoaster - Medivir´s Previous Four Months (and Biotech Today in 2026)

Jens Lindberg, CEO at Medivir, on The Biotech Rollercoaster - Medivir´s Previous Four Months (and Biotech Today in 2026)

In this episode, I talked with Jens Lindberg, CEO of Medivir AB, a Swedish biotech developing innovative therapies in liver cancer and rare disease. Jens brings over 30 years of late-stage development...

18 Touko 33min

Hubert Truebel,  Managing Director at DEBRA Research, on Creating Own Career Opportunities...and a Practical Approach to Longevity

Hubert Truebel, Managing Director at DEBRA Research, on Creating Own Career Opportunities...and a Practical Approach to Longevity

In this episode, I talked with Hubert Truebel, Managing Director at DEBRA Research, to discover a career that wasn’t built traditionally—but through creating opportunities where none formally existed....

4 Touko 28min

Sampreet Ramachandra, Head of Hematology Business Unit at Novartis Germany, on Launching Without a Playbook, Hiring Mistakes, and Leading with Equity

Sampreet Ramachandra, Head of Hematology Business Unit at Novartis Germany, on Launching Without a Playbook, Hiring Mistakes, and Leading with Equity

In this episode, I talked with Sampreet Ramachandra, Head of the Hematology Business Unit at Novartis Germany, about what it really takes to lead high-stakes launches — and what leadership looks like ...

30 Maalis 42min

Suosittua kategoriassa Liike-elämä ja talous

sijotuskasti
vallattomat
psykopodiaa-podcast
rss-rahapodi
mimmit-sijoittaa
rss-oivalluksia-rahasta-elamasta
ostan-asuntoja-podcast
lakicast
oppimisen-psykologia
rss-inderes
rss-paasipodi
juristipodi
hyva-paha-johtaminen
rss-karon-grilli
rss-rahamania
rss-pinnan-alle
rss-alanvaihtajat
rss-startup-ministerio
rahapuhetta
rss-siksi-viestinta